Targeted overexpression of mitochondrial catalase protects against cancer chemotherapy-induced skeletal muscle dysfunction

The loss of strength in combination with constant fatigue is a burden on cancer patients undergoing chemotherapy. Doxorubicin, a standard chemotherapy drug used in the clinic, causes skeletal muscle dysfunction and increases mitochondrial H(2)O(2). We hypothesized that the combined effect of cancer...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Am J Physiol Endocrinol Metab
Prif Awduron: Gilliam, Laura A. A., Lark, Daniel S., Reese, Lauren R., Torres, Maria J., Ryan, Terence E., Lin, Chien-Te, Cathey, Brook L., Neufer, P. Darrell
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Physiological Society 2016
Pynciau:
Call for Papers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5005971/
https://ncbi.nlm.nih.gov/pubmed/27329802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpendo.00540.2015
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg